Market Place
Sourcing Support
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
13 Sep 2024 //
GLOBENEWSWIRE
ONL Therapeutics To Present At 57th Retina Society Meeting
10 Sep 2024 //
GLOBENEWSWIRE
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
06 Feb 2024 //
GLOBENEWSWIRE
ONL Therapeutics to Present on ONL1204 in Podium Presentation
23 Jan 2024 //
GLOBENEWSWIRE
ONL Therapeutics Completes Enrollment in Ph2 Study First-in-Class Fas-Inhibitor
28 Aug 2023 //
GLOBENEWSWIRE
ONL Announces First Patient Dosed in PII Trial of First-in-Class Fas-Inhibitor
12 Apr 2023 //
GLOBENEWSWIRE
ONL Therapeutics to Report Data on ONL1204 in Podium Presentation at ARVO
11 Apr 2023 //
GLOBENEWSWIRE
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing
08 Mar 2023 //
GLOBENEWSWIRE
ONL Therapeutics to Present at Biennial Meeting of the International Society
13 Feb 2023 //
GLOBENEWSWIRE
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
02 Feb 2023 //
GLOBENEWSWIRE
ONL Receive FDA Clearance of Investigational NDA for ONL1204 Ophthalmic Solution
01 Feb 2023 //
GLOBENEWSWIRE
ONL to Highlight Data in Presentations at 46th Annual Macula Society Meeting
26 Jan 2023 //
GLOBENEWSWIRE
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing for PII Study
12 Jul 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.